Beximco Pharmaceuticals Limited 

€0.4
17
-€0.01-2.44% Wednesday 06:20

Statistics

Day High
0.42
Day Low
0.41
52W High
-
52W Low
-
Volume
8,500
Avg. Volume
-
Mkt Cap
0
P/E Ratio
4
Dividend Yield
7.84%
Dividend
0.03

Upcoming

Dividends

7.84%Dividend Yield
Feb 26
€0.03
Feb 25
€0.03
Feb 24
€0.03
Mar 23
€0.03
Feb 22
€0.03
10Y Growth
11.61%
5Y Growth
N/A
3Y Growth
-0.72%
1Y Growth
N/A

Earnings

11NovExpected
Q3 2020
Q4 2020
Q1 2021
Q3 2021
Q4 2021
Q1 2022
Q3 2022
2.14
2.54
2.93
3.32
Expected EPS
N/A
Actual EPS
2.8679

Financials

13.18%Profit Margin
Profitable
2018
2019
2020
2021
2022
2023
41.02BRevenue
5.41BNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow R2WA.F. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Innoviva
INVA
Mkt Cap1.15B
InvaGen Pharmaceuticals Inc. competes in the generics market, offering a portfolio that overlaps with Beximco's, particularly in the US market.
Teva- Pharmaceutical Industries
TEVA
Mkt Cap23.49B
Teva Pharmaceutical Industries Limited is a global leader in generic medicines, directly competing with Beximco's offerings in multiple international markets.
Dr. Reddy`s Laboratories
RDY
Mkt Cap11.25B
Dr. Reddy's Laboratories Ltd. is an Indian multinational pharmaceutical company that competes with Beximco in the generics and active pharmaceutical ingredients (API) sectors.
Accenture
ACN
Mkt Cap155.1B
ACME Laboratories Ltd. is another key competitor in the Bangladeshi pharmaceutical sector, competing directly with Beximco in terms of product range and market share.
GSK
GSK
Mkt Cap94.51B
GlaxoSmithKline plc is a global pharmaceutical company whose diverse product line in pharmaceuticals and vaccines competes with Beximco's products in various markets.
Novartis
NVS
Mkt Cap237.61B
Novartis AG is a Swiss multinational pharmaceutical company that competes with Beximco in the development and marketing of drugs in similar therapeutic areas.
Pfizer
PFE
Mkt Cap140.15B
Pfizer Inc. is a global pharmaceutical corporation that competes with Beximco in the innovation, development, and distribution of pharmaceuticals and vaccines.
Abbvie
ABBV
Mkt Cap385.18B
AbbVie Inc. competes with Beximco through its broad range of pharmaceutical products, particularly in therapeutic areas where Beximco is also active.
Merck
MRK
Mkt Cap214.76B
Merck & Co., Inc. is a global healthcare company that competes with Beximco in the discovery, development, and marketing of pharmaceuticals and vaccines.

About

Beximco Pharmaceuticals Limited manufactures and markets generic pharmaceutical formulations and active pharmaceutical ingredients in Bangladesh. The company provides allergic disorder, analgesics and antipyretic, anti-infective, antiviral, cardiovascular, central nervous system, cough and cold, endocrine and diabetes, eye care, gastrointestinal, hormone and steroid, intravenous fluid, musculoskeletal, oncology, respiratory, urogenital, skin care, vitamin and mineral supplement, and other products, as well as contract manufacturing services to other companies. It offers its products in various dosage forms, including solid, liquid, cream and ointment, suppositories, metered dose and dry powder inhaler, nasal spray, sterile, lyophilized injectable, and large volume intravenous fluids. The company also exports its products. Beximco Pharmaceuticals Limited was incorporated in 1976 and is headquartered in Dhaka, Bangladesh.
Show more...
CEO
Mr. Iqbal U. Ahmed
Employees
6000
Country
BD
ISIN
US0885792061
WKN
000A0ETTX

Listings

0 Comments

Share your thoughts

FAQ

What is Beximco Pharmaceuticals Limited stock price today?
The current price of R2WA.F is €0.4 EUR — it has decreased by -2.44% in the past 24 hours. Watch Beximco Pharmaceuticals Limited stock price performance more closely on the chart.
What is Beximco Pharmaceuticals Limited stock ticker?
Depending on the exchange, the stock ticker may vary. For instance, on exchange Beximco Pharmaceuticals Limited stocks are traded under the ticker R2WA.F.
Is Beximco Pharmaceuticals Limited stock price growing?
R2WA.F stock has risen by +0% compared to the previous week, the month change is a +0% rise, over the last year Beximco Pharmaceuticals Limited has showed a -8.68% decrease.
What is Beximco Pharmaceuticals Limited revenue for the last year?
Beximco Pharmaceuticals Limited revenue for the last year amounts to 41.02B EUR.
What is Beximco Pharmaceuticals Limited net income for the last year?
R2WA.F net income for the last year is 5.41B EUR.
Does Beximco Pharmaceuticals Limited pay dividends?
Yes, R2WA.F dividends are paid annual. The last dividend per share was 0.03 EUR. As of today, Dividend Yield (FWD)% is 7.84%.
How many employees does Beximco Pharmaceuticals Limited have?
As of April 05, 2026, the company has 6,000 employees.
In which sector is Beximco Pharmaceuticals Limited located?
Beximco Pharmaceuticals Limited operates in the Health Care sector.
When did Beximco Pharmaceuticals Limited complete a stock split?
The last stock split for Beximco Pharmaceuticals Limited was on November 23, 2020 with a ratio of 1.1:1.
Where is Beximco Pharmaceuticals Limited headquartered?
Beximco Pharmaceuticals Limited is headquartered in Dhaka, BD.